Chemoradiation therapy using IMRT followed by durvalumab for locally advanced NSCLC: a multicenter prospective single arm study(WJOG12019L)
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000038366
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Active double cancer 2. Infection which requires systemic antibiotics 3. Obvious interstitial lung disease or pulmonary fibrosis by chest-CT 4. Uncontrolled comorbidities such as diabetes, hypertension, heart failure, arrythmia, thrombo-embolism, psychotic disease, liver cirrhosis, and/or renal failure) 5. HIV-associated disease 6. Prescription of systemic steroids or immunosuppressant
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Durvalumab induction rate (rate of cases where durvalumab can be introduced within 42 days after CRT completion)
- Secondary Outcome Measures
Name Time Method